AFL Q1 Deep Dive: Missed Expectations as Japan Sales Offset by Premium Pressure
Supplemental insurance provider Aflac (NYSE:AFL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.8% year on year to $4.24 billion. Its non-GAAP profit of $1.75 per share was 2.5% below analysts’ consensus estimates. Aflac (AFL) Q1 CY2026 Highlights: Revenue: $4.24 billion vs analyst estimates of $4.32 billion (1.8% year-on-year decline, 1.7% miss) Adjusted EPS: $1.75 vs analyst expectations of $1.80 (2.5% miss) Adjusted Operating Income: $1.12 billion vs analyst estimates of $1.19 billion (26.4% margin, 6% miss) Market Capitalization: $59.87 billion StockStory’s Take Aflac’s first quarter results fell short of Wall Street’s expectations, with both revenue and adjusted earnings per share missing consensus estimates. The market responded negatively, with shares declining after the announcement. Management highlighted strong sales momentum in Japan, particularly from new medical and cancer insurance products, but acknowledged ongoing challenges in maintaining earned premium growth. CEO Daniel Amos pointed to the company’s focus on persistency and distribution channel expansion as key operational themes, while CFO Max Broden discussed pressures from lapses and the impact of reinsurance transactions on near-term earnings. Looking ahead, Aflac’s guidance is shaped by its ability to grow sales in both Japan and the U.S., while navigating persistency challenges and changes in customer mix. Management sees opportunity in expanding their reinsurance franchise in Japan and expects sales of core products to remain robust. However, CFO Max Broden cautioned that improving earned premium growth will require sustained sales momentum, stating, “We have a line of sight of getting to that level, but for the time being, we expect to remain in the range of negative 1% to 2% on underlying earned premium.” Key Insights from Management’s Remarks Management attributed the quarter’s underperformance to softer earned premiums in Japan, higher lapses, and near-term headwinds from a new external reinsurance transaction, while emphasizing ongoing product momentum and disciplined cost control.